



Con il patrocinio di



## BARI

SALA CONGRESSI  
Istituto Tumori  
Giovanni Paolo II  
IRCCS

Viale Orazio Flacco, 65



**6 LUGLIO 2018**

**RETE ONCOLOGICA IN PUGLIA**  
**COME RIDURRE LA MOBILITÀ PASSIVA**

2018 **MOTORE**  
**SANITÀ**  
Sanità Universale

## LE ALLEANZE A SUD DELLA RICERCA E DELLA CLINICA PER L'ONCOLOGIA

**Nicola Silvestris**, Direttore Scientifico Istituto Tumori  
IRCCS Giovanni Paolo II Bari



“ L’unico imperativo è l’instabilità e la precarietà: è  
**una società che sfugge, in continuo  
cambiamento, “liquida”...**



Silvestris et al. *Journal of Experimental & Clinical Cancer Research* (2017) 36:128  
DOI 10.1186/s13046-017-0598-x


Journal of Experimental &  
Clinical Cancer Research

REVIEW

Open Access



# Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research

Nicola Silvestris<sup>1\*</sup> , Gennaro Ciliberto<sup>2</sup>, Paolo De Paoli<sup>3</sup>, Giovanni Apolone<sup>4</sup>, Maria Luisa Lavitrano<sup>5</sup>, Marco A. Pierotti<sup>6</sup>, Giorgio Stanta<sup>7</sup> and On the behalf of the "dynamic medicine OECD group"

# Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research


Nicola Silvestris<sup>1\*</sup>, Gennaro Ciliberto<sup>2</sup>, Paolo De Paoli<sup>3</sup>, Giovanni Apolone<sup>4</sup>, Maria Luisa Lavitrano<sup>5</sup>, Marco A. Pierotti<sup>6</sup>, Giorgio Stanta<sup>7</sup> and On the behalf of the "dynamic medicine OECl group"

This article was conceived at the OECl oncology days 2017 in BRNO, 23 June 2017.



Journal of Experimental &  
Clinical Cancer Research

(2017)




This goal could be possible to achieve with ***studies focusing on a single person*** – known as ***N-of-1 trials*** – which aim to study targeted treatments for tumors in individual patients

***The option we propose is to compare the time-to-disease progression of an individual cancer patient following treatment with a novel therapy to the time-to-disease progression for the same patient on his/her immediately previous treatment***

***In other words, in N-of-1 trials the same patient will be the tester of a new therapy and its control arm***



Le reti oncologiche come una sorta di centri neuronali  
***la cui forza viene dalle connessioni***



Le reti hanno la loro forza nelle  
***connessioni che sanno creare tra i vari centri***

# The Cancer Moonshot 2020 Initiative

## *Obama Takes First Step in a Cancer ‘Moonshot’*

---



January 28, 2016

### 2016 State of the Union Address

***“For the loved ones we’ve all lost, for the family we can still save, let’s make America the country that cures cancer once and for all”***



## Briefing Room

Your Weekly Address

Speeches & Remarks

Press Briefings

Statements & Releases

White House Schedule

Presidential Actions

Executive Orders

**Presidential Memoranda**

Proclamations

Legislation

Nominations &  
Appointments

Disclosures

# Memorandum -- White House Cancer Moonshot Task Force

January 28, 2016

SUBJECT: White House Cancer Moonshot Task Force

It is of critical national importance that we accelerate progress towards prevention, treatment, and a cure -- to double the rate of progress in the fight against cancer -- and put ourselves on a path to achieve in just 5 years research and treatment gains that otherwise might take a decade or more.

Section 1. White House Cancer Moonshot Task Force. There is established, within the Office of the Vice President, a White House Cancer Moonshot Task Force (Task Force), which will focus on making the most of Federal investments, targeted incentives, private sector efforts from industry and philanthropy, patient engagement initiatives, and other mechanisms to support cancer research and enable progress in treatment and care. The Vice President shall serve as Chair of the Task Force.



**The Cancer Moonshot Task Force brought together all relevant federal agencies and fostered more than 70 private sector collaborations to focus on transforming cancer research and care.**



# Cancer Moonshot 2020



**“Cancer MoonShot 2020” is a historic national coalition of pharmaceutical companies, biotech, major payers, community oncologists, and academia**



# Cancer Moonshot Blue Ribbon Panel

- The US Congress provided **\$1.8 billion over 7 years** for the Beau Biden Cancer Moonshot (an average of almost \$260 million per year) to support the implementation of the BRP's recommendations
- Not guaranteed, must still be appropriated every year




## The Cancer Moonshot from a European perspective

*Fortunato Ciardiello, Josep Tabernero*

***Large disparities in national cancer research programmes and actions*** in cancer care still exist between EU countries

All scientific organizations within the cancer research community, as noted by the European Society for Medical Oncology, have a duty to work together and to cooperate with all the public and private stakeholders, at both the national and EU level, ***to identify cancer research priorities and promote accordingly sustainable and feasible actions***



See [The Lancet Oncology Commission](#) page e653

# ESMO 2020 VISION



In 2015, the ESMO 2020 Vision identified three major trends for short and mid-term developments in oncology:

## 1 INTEGRATED CANCER CARE

Bridging cancer prevention, research, early-diagnosis, and treatment to improve patient outcomes

## 2 SPECIALISED EDUCATION

Supporting oncologists in a fast-changing professional environment

## 3 SUSTAINABLE CANCER CARE

Advocating for equal access to quality treatment and for cancer prevention

## Founders



Regina Elena, Rome



Fond. Maugeri,  
Milan



IDI, Rome



Fond. Besta,  
Milan



Humanitas,  
Milan



IEO, Milan



IOR, Bologna

## Ordinary Members



San Raffaele, Milan



istituto  
oncologico  
romagnolo

IOR, Meldola



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Azienda Ospedaliera di Reggio Emilia  
Arcispedale S. Maria Nuova

Arcispedale S. Maria Nuova, RE



Fondazione  
del Piemonte  
per l'Oncologia

IRCC Candiolo, TO



SDN, Naples

# Il ruolo di Alleanza Contro il Cancro nella ricerca

## PROFILO

ACC, la più grande organizzazione di ricerca oncologica italiana, è stata fondata nel 2002 dal Ministero della Salute tra sei centri di alto livello di cura e ricerca del cancro (IRCCS).

L'Associazione è attualmente formata da 21 Istituti di Ricovero e Cura a Carattere Scientifico, AIMac, l'Associazione italiana dei malati oncologici, Italian Sarcoma Group e l'Istituto Superiore di Sanità, che ne ospita gli uffici.

La missione di ACC è **promuovere la rete** tra centri oncologici con finalità di ricerca primariamente clinica e traslazionale per «portare al letto del paziente» le innovazioni diagnostiche e le più avanzate procedure terapeutiche.

sù  
ico  
e


## Adherent Associates



## New Members









[Membership](#) / [Italy](#) / Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico

Country's Members list



## Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico






# Oncology Days

**OECC 41**  
**BARI 2019**  
**GENERAL ASSEMBLY,  
 SCIENTIFIC CONFERENCES  
 AND RELATED EVENTS**

Bari, Italy  
 June 19<sup>th</sup>-24<sup>th</sup> 2019



*Grazie!*



[n.silvestris@oncologico.bari.it](mailto:n.silvestris@oncologico.bari.it)